LHLi Huang

Li Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Li Huang has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Congying Chen

    Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    2 shared publications
  • Lijuan Yang

    Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Gastroenterol, Sch Med, 100 Haining Rd, Shanghai 200080, Peoples R China

    2 shared publications
  • Bin Hu

    Department of Gastroenterology and

    1 shared publication
  • Congying Chen

    Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

    1 shared publication
  • Dachuan Qi

    Second Department of General Surgery, Longhua Hospital, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China

    1 shared publication
  • Daoheng Wang

    Second Department of General Surgery, Longhua Hospital, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China

    1 shared publication

Latest Publications

  • Open Access

    CUL2 confers ferroptosis resistance in pancreatic cancer by disrupting KEAP1-mediated NRF2 degradation

    by Kui Yu, LiLi Chen, Yong Zhong, Yang Wang, Na Zhu, Daoheng Wang, Wenyan Yao, Haoran Bai, Lijuan Yang, Dachuan Qi

    Pancreatic cancer (PC) is characterized by high chemoresistance and poor prognosis. CUL2, a scaffold protein of E3 ubiquitin ligases, has been implicated i


  • Open Access

    Improving trainee colonoscopy performance by investigating the withdrawal time from individual colonic segments: a single-center observational study

    by Yinshi Huang, Feifan Chen, Gang Xu, Li Huang, Rong Wan, Lijuan Yang, Congying Chen

    Background: The colonoscopy withdrawal time (WT) and adenoma detection rate (ADR) are widely used quality indicators for colonoscopy. However, no study has investigated the appropriate colonoscopy WTs of individual colonic segments that will allow trainees to achieve a higher ADR. Thus, we analyzed for the first time the relationship between colonoscopy WT and the ADR/polyp detection rate (PDR) in the proximal, left-sided and entire colon among trainees. Methods: This retrospective study involved 611 consecutive patients who underwent colonoscopy from March 2018 to March 2019 performed by 6 trainees in the Endoscopy Center of Shanghai General Hospital. The WTs for the individual colonic segments and any significant findings of colonoscopies were retrospectively retrieved from the trainees’ records and verified in the endoscopy center database. ADR/PDR was defined as the number of colonoscopies detecting at least 1 polyp/adenoma divided by the total number of colonoscopies. Comparisons of PDR and ADR between the 2 groups were conducted using chi-square test. Multilevel analysis was performed to consider individual differences among the 6 trainees. Multilevel binary logistic regression analysis was performed to analyze the factors that influenced the PDR, ADR and advanced adenoma detection rate (AADR) for the entire colon, and trainee status was included as a random effect. Results: The mean WTs were 4.20±1.09, 4.27±1.12, and 8.48±1.87 minutes for the proximal, left-sided, and entire colon, respectively. A longer WT [odds ratio (OR) 1.499, 95% confidence interval (CI): 1.381–1.628, PConclusions: In order to improve trainee colonoscopy performance, trainees were recommended to have WTs of at least 4 minutes in the proximal colon, 4 minutes in the left-sided colon and 8 minutes in the entire colon during negative screening colonoscopies.


  • Retracted
    Open Access

    RETRACTED: GATA4 Regulates Inflammation-Driven Pancreatic Ductal Adenocarcinoma Progression

    by Weiliang Jiang, Congying Chen, Li Huang, Jie Shen, Lijuan Yang

    Cancer-associated inflammation is a key molecular feature in the progression of pancreatic ductal adenocarcinoma (PDAC). GATA4 is a transcription factor that participates in the regulation and normal development of several endoderm- and mesoderm-derived tissues such as the pancreas. However, it remains unclear whether GATA4 is involved in the inflammation-driven development of pancreatic cancer. Here, we employed quantitative reverse transcription PCR, immunohistochemistry, and differential expression analysis to investigate the association between GATA4 and inflammation-driven PDAC. We found that overexpression of GATA4 in pancreatic tumor tissue was accompanied by increased levels of inflammatory macrophages. We used macrophage-conditioned medium to validate inflammation models following treatment with varying concentrations of lipopolysaccharide and determined whether GATA4-dependent inflammatory stimuli affected pancreatic cancer cell invasion and growth in vitro. Nude mouse models of dibutyltin dichloride-induced chronic pancreatitis with orthotopic tumor xenografts were used to evaluate the effect of the inflammatory microenvironment on GATA4 expression in vivo. Our findings indicate that overexpression of GATA4 dramatically aggravated inflammatory stimuli-induced pancreatic cancer cell invasion and growth via NF-κB and STAT3 signaling, whereas silencing of GATA4 attenuated invasion and growth. Overall, our findings suggest that inflammation-driven cancer progression is dependent on GATA4 expression and is mediated through the STAT3 and NF-κB signaling pathways.


  • Retracted
    Open Access

    RETRACTED ARTICLE: Transcriptional repression of SOCS3 mediated by IL-6/STAT3 signaling via DNMT1 promotes pancreatic cancer growth and metastasis

    by Li Huang, Bin Hu, Jianbo Ni, Jianghong Wu, Weiliang Jiang, Congying Chen, Lijuan Yang, Yue Zeng, Rong Wan, Guoyong Hu, et al.

    Background: Previous studies have investigated the sustained aberrantly activated Interleukin-6 (IL-6)/signal transducer and activator of transcription 3 (STAT3) signaling pathway is crucial for pancreatic cancer growth and metastasis. Suppressor of cytokine signaling 3 (SOCS3), as a key negative feedback regulator of this signaling pathway, is usually down-regulated in various cancers. In the present study, we aim at exploring the biological function and the underlying molecular regulation mechanisms of SOCS3 in pancreatic cancer. Methods: The expression of SOCS3 and other genes in pancreatic cancer was examined by Quantitative real-time PCR, western blotting and immunohistochemical staining. The interaction between pSTAT3 and DNA Methyltransferase 1 (DNMT1) was investigated by co-immunoprecipitation assay. Luciferase reporter assay was used to investigate the transcriptional regulation of pSTAT3 and DNMT1 on the SOCS3 gene. The effects of SOCS3 on the biological behavior of pancreatic cancer cells were assessed both in vitro and vivo. Furthermore, we performed a comprehensive analysis of the expression of SOCS3 in a pancreatic cancer tissue microarray (TMA) and correlated our findings with pathological parameters and outcomes of the patients. Results: We showed that SOCS3 expression was decreased in phosphorylated STAT3 (pSTAT3)-positive tumors and was negatively correlated with pSTAT3 in pancreatic cancer cells. We also found that IL-6/STAT3 promoted SOCS3 promoter hypermethylation by increasing DNMT1 activity; silencing DNMT1 or 5-aza-2-deoxycytidine (5-AZA) treatment could reverse the down-regulation of SOCS3 mediated by IL-6. Using co-immunoprecipitation and luciferase reporter assays, we found that STAT3 recruited DNMT1 to the promoter region of SOCS3 and inhibited its transcriptional activity. Overexpression of SOCS3 significantly inhibited cell proliferation, which may be due to the increase in G1-S phase arrest; overexpression of SOCS3 also inhibited cell migration and invasion as well as tumorigenicity in nude mice. Pancreatic cancer tissue microarray analysis showed that high SOCS3 expression was a good prognostic factor and negatively correlated with tumor volume and metastasis. Conclusion: We demonstrated that activated IL-6/STAT3 signaling could induce SOCS3 methylation via DNMT1, which led to pancreatic cancer growth and metastasis. These data also provided a mechanistic link between sustained aberrantly activated IL-6/STAT3 signaling and SOCS3 down-regulation in pancreatic cancer. Thus, inhibitors of STAT3 or DNMT1 may become novel strategies for treating pancreatic cancer.